These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35581005)

  • 1. Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data.
    Rowles WM; Hsu WY; McPolin K; Li A; Merrill S; Guo CY; Green AJ; Gelfand JM; Bove RM
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35581005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
    Delgado S; Hernandez J; Tornes L; Rammohan K
    BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.
    Rollot F; Couturier J; Casey R; Wiertlewski S; Debouverie M; Pelletier J; De Sèze J; Labauge P; Ruet A; Thouvenot E; Ciron J; Berger E; Gout O; Clavelou P; Stankoff B; Casez O; Bourre B; Zephir H; Moreau T; Lebrun-Frenay C; Maillart E; Edan G; Neau JP; Montcuquet A; Cabre P; Camdessanché JP; Defer G; Nasr HB; Maurousset A; Hankiewicz K; Pottier C; Leray E; Vukusic S; Laplaud DA
    Neurotherapeutics; 2022 Mar; 19(2):476-490. PubMed ID: 35217934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
    Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M
    Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
    Jouvenot G; Courbon G; Lefort M; Rollot F; Casey R; Le Page E; Michel L; Edan G; de Seze J; Kremer L; Bigaut K; Vukusic S; Mathey G; Ciron J; Ruet A; Maillart E; Labauge P; Zephir H; Papeix C; Defer G; Lebrun-Frenay C; Moreau T; Laplaud DA; Berger E; Stankoff B; Clavelou P; Thouvenot E; Heinzlef O; Pelletier J; Al-Khedr A; Casez O; Bourre B; Cabre P; Wahab A; Magy L; Camdessanché JP; Doghri I; Moulin S; Ben-Nasr H; Labeyrie C; Hankiewicz K; Neau JP; Pottier C; Nifle C; Collongues N; Kerbrat A;
    JAMA Neurol; 2024 May; 81(5):490-498. PubMed ID: 38526462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
    J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
    Signoriello E; Lus G; Bonavita S; Lanzillo R; Saccà F; Landi D; Frau J; Baroncini D; Zaffaroni M; Maniscalco GT; Curti E; Sartori A; Cepparulo S; Marfia GA; Nicoletti CG; Carotenuto A; Nociti V; Caleri F; Sormani MP; Signori A
    Mult Scler; 2022 Jan; 28(1):93-101. PubMed ID: 33855897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
    Nygaard GO; Torgauten H; Skattebøl L; Høgestøl EA; Sowa P; Myhr KM; Torkildsen Ø; Celius EG
    Mult Scler Relat Disord; 2022 Jun; 62():103812. PubMed ID: 35462167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
    Ferraro D; Iaffaldano P; Guerra T; Inglese M; Capobianco M; Brescia Morra V; Zaffaroni M; Mirabella M; Lus G; Patti F; Cavalla P; Cellerino M; Malucchi S; Pisano E; Vitetta F; Paolicelli D; Sola P; Trojano M;
    J Neurol; 2022 Mar; 269(3):1463-1469. PubMed ID: 34292396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.
    Al-Hashel J; Ahmed SF; Behbehani R; Alroughani R
    CNS Drugs; 2014 Sep; 28(9):817-24. PubMed ID: 25011422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What happens after fingolimod discontinuation? A multicentre real-life experience.
    Landi D; Signori A; Cellerino M; Fenu G; Nicoletti CG; Ponzano M; Mancuso E; Fronza M; Ricchiuto ME; Boffa G; Inglese M; Marfia GA; Cocco E; Frau J
    J Neurol; 2022 Feb; 269(2):796-804. PubMed ID: 34136943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical activity after fingolimod cessation: disease reactivation or rebound?
    Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
    Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivation.
    Gassama S; Garmendia A; Lejeune FX; Boudot de la Motte M; Louapre C; Papeix C; Maillart E; Roux T
    Rev Neurol (Paris); 2023 Nov; 179(9):1035-1038. PubMed ID: 37633735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
    Tichá V; Kodým R; Počíková Z; Kadlecová P
    Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
    Sánchez P; Meca-Lallana V; Vivancos J
    Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
    Meinl I; Havla J; Hohlfeld R; Kümpfel T
    Mult Scler; 2018 Jun; 24(7):991-994. PubMed ID: 28920764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
    Boz C; Terzi M; Özer B; Turkoglu R; Karabudak R; Efendi H; Soysal A; Sevim S; Altintas A; Kurne A; Akçalı A; Akman G; Yüceyar N; Balcı BP; Ekmekci Ö; Karahan SZ; Demirkıran M; Altunrende B; Turan ÖF; Gökçen GözübatıkÇelik ; Kale N; Köseoğlu M; Ozakbas S
    Mult Scler Relat Disord; 2019 Nov; 36():101376. PubMed ID: 31473488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and risk factors of rebound after fingolimod discontinuation - A retrospective study.
    Maunula A; Atula S; Laakso SM; Tienari PJ
    Mult Scler Relat Disord; 2024 Jan; 81():105134. PubMed ID: 37980790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.